<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30362065</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1534-4681</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>25</Day>                    </PubDate>                </JournalIssue>                <Title>Annals of surgical oncology</Title>                <ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-018-6937-0</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A diagnosis of non-classic lobular carcinoma in situ (NC-LCIS) encompasses a variety of lesions with poorly characterized natural history. We evaluated upgrade rates and factors associated with upgrade to malignancy following a core biopsy diagnosis of NC-LCIS, and its natural history.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Upon Institutional Review Board approval, pathology databases were searched for NC-LCIS core biopsy diagnoses (carcinoma in situ [CIS], CIS with ductal and lobular features [CIS/DLF], pleomorphic LCIS [P-LCIS], variant LCIS [V-LCIS], LCIS with necrosis). Cases with available core and excision pathology were included, while cases with concurrent ipsilateral invasive carcinoma (IC), ductal carcinoma in situ (DCIS), and/or atypical ductal hyperplasia were excluded.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 121 NC-LCIS cases were identified from 1998 to 2017. We excluded 46 cases with concurrent cancer; 75 patients with 76 NC-LCIS core biopsy diagnoses followed by excision formed our study cohort. Median age was 56 years (range 41-83), and all imaging findings were classified as Breast Imaging Reporting and Data System 4; calcifications were the most common biopsy indication (80%). Excision yielded malignancy in 27 (36%) patients (IC 17, 63%; DCIS alone 10, 37%). We were unable to identify radiologic or pathologic features predictive of upgrade. Of 49 pure NC-LCIS cases, 15 (31%) had mastectomy, 9 (18%) had excision and radiation, and 25 (51%) had excision alone. At a median follow-up of 58 months (range 1-224), 1/25 (4%) patients with excision alone developed ipsilateral DCIS 14 months later.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this series of NC-LCIS, 36% of cases were upgraded, supporting routine excision. We were unable to identify predictors of upgrade. Among 25 patients with pure NC-LCIS, only one patient developed a future ipsilateral cancer. Further study of the natural history of NC-LCIS is warranted.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nakhlis</LastName>                    <ForeName>Faina</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harrison</LastName>                    <ForeName>Beth T</ForeName>                    <Initials>BT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giess</LastName>                    <ForeName>Catherine S</ForeName>                    <Initials>CS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lester</LastName>                    <ForeName>Susan C</ForeName>                    <Initials>SC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hughes</LastName>                    <ForeName>Kevin S</ForeName>                    <Initials>KS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coopey</LastName>                    <ForeName>Suzanne B</ForeName>                    <Initials>SB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>King</LastName>                    <ForeName>Tari A</ForeName>                    <Initials>TA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. tking7@bwh.harvard.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Harvard Cancer Center, Boston, MA, USA. tking7@bwh.harvard.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. tking7@bwh.harvard.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Ann Surg Oncol</MedlineTA>            <NlmUniqueID>9420840</NlmUniqueID>            <ISSNLinking>1068-9265</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30362065</ArticleId>            <ArticleId IdType="doi">10.1245/s10434-018-6937-0</ArticleId>            <ArticleId IdType="pii">10.1245/s10434-018-6937-0</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>